Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.

Phase 3

Novartis

Imatinib Mesylate